Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J Wolbink

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
The Lancet. Rheumatology|January 3, 2022
Rituximab during the COVID-19 pandemic: time to discuss treatment options with patientsL Boekel, G J Wolbink
Clinical Rheumatology|July 27, 2013
Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseasesC C Mok, D van der Kleij, G J Wolbink
Clinical Immunology and Immunopathology|July 1, 1994
Re: Pathways of complement activation in sepsisC E Hack, G J Wolbink, P M Jansen, et al.
Annals of the Rheumatic Diseases|January 14, 2005
Bone mineral density in patients with rheumatoid arthritis treated with infliximabM Vis, A E Voskuyl, G J Wolbink, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1996
CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexesG J Wolbink, M C Brouwer, S Buysmann, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 1995
Therapy with interleukin-2 induces the systemic release of phospholipase-A2G J Wolbink, C Schalkwijk, J W Baars, et al.
Immunology Today|March 1, 1997
A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cellsC E Hack, G J Wolbink, C Schalkwijk, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Renal cell carcinoma and interleukin-2: a reviewJ Wagstaff, J W Baars, G J Wolbink, et al.
Scandinavian Journal of Rheumatology|November 2, 2021
Elevated Fab glycosylation of anti-hinge antibodiesJ Koers, Nil Derksen, Wjj Falkenburg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1992
Angioneurotic oedema and urticaria during therapy with interleukin-2 (IL-2)J W Baars, J Wagstaff, C E Hack, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
The Lancet. Rheumatology|January 3, 2022
Rituximab during the COVID-19 pandemic: time to discuss treatment options with patientsL Boekel, G J Wolbink
Clinical Rheumatology|July 27, 2013
Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseasesC C Mok, D van der Kleij, G J Wolbink
Clinical Immunology and Immunopathology|July 1, 1994
Re: Pathways of complement activation in sepsisC E Hack, G J Wolbink, P M Jansen, et al.
Annals of the Rheumatic Diseases|January 14, 2005
Bone mineral density in patients with rheumatoid arthritis treated with infliximabM Vis, A E Voskuyl, G J Wolbink, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 1996
CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexesG J Wolbink, M C Brouwer, S Buysmann, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 1995
Therapy with interleukin-2 induces the systemic release of phospholipase-A2G J Wolbink, C Schalkwijk, J W Baars, et al.
Immunology Today|March 1, 1997
A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cellsC E Hack, G J Wolbink, C Schalkwijk, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Renal cell carcinoma and interleukin-2: a reviewJ Wagstaff, J W Baars, G J Wolbink, et al.
Scandinavian Journal of Rheumatology|November 2, 2021
Elevated Fab glycosylation of anti-hinge antibodiesJ Koers, Nil Derksen, Wjj Falkenburg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1992
Angioneurotic oedema and urticaria during therapy with interleukin-2 (IL-2)J W Baars, J Wagstaff, C E Hack, et al.
Pageof 7